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Abstract
Trypanosomatid parasites are notorious for the human diseases they cause throughout Africa and South America. However,
non-pathogenic trypanosomatids are also found worldwide, infecting a wide range of hosts. One example is Trypanosoma
(Megatrypanum) theileri, a ubiquitous protozoan commensal of bovids, which is distributed globally. Exploiting knowledge
of pathogenic trypanosomatids, we have developed Trypanosoma theileri as a novel vehicle to deliver vaccine antigens and
other proteins to cattle. Conditions for the growth and transfection of T. theileri have been optimised and expressed
heterologous proteins targeted for secretion or specific localisation at the cell interior or surface using trafficking signals
from Trypanosoma brucei. In cattle, the engineered vehicle could establish in the context of a pre-existing natural T. theileri
population, was maintained long-term and generated specific immune responses to an expressed Babesia antigen at
protective levels. Building on several decades of basic research into trypanosomatid pathogens, Trypanosoma theileri offers
significant potential to target multiple infections, including major cattle-borne zoonoses such as Escherichia coli, Salmonella
spp., Brucella abortus and Mycobacterium spp. It also has the potential to deliver therapeutics to cattle, including the lytic
factor that protects humans from cattle trypanosomiasis. This could alleviate poverty by protecting indigenous African
cattle from African trypanosomiasis.
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Introduction
Human health is intimately linked to animal health through the
impact of infectious agents on livestock productivity and their
potential for zoonosis [1]. Indeed, animal borne disease represents
the major source of both emergent and resurgent pathogens in
humans, this affecting communities in both the developed and
developing world. One major source of such zoonotic infections is
cattle, which threaten human health in the developed world
through their capacity to transmit bacterial infections including
Escherichia coli, Salmonella spp., Campylobacter spp., Brucella spp. and
mycobacteria. In the developing world, livestock are also a
reservoir for Human African Trypanosomiasis (HAT) caused by
Trypanosoma brucei rhodesiense. This parasite, and Trypanosoma brucei
gambiense, is closely related to Trypanosoma brucei brucei, which cannot
infect humans. The basis of this host restriction is that human
serum contains a trypanolytic component of high-density lipopro-
tein, ApoLI, that kills T. brucei brucei [2], but to which the human
infective parasites have evolved resistance [3,4].
Although trypanosomes are important causes of human and
animal disease, many species are non-pathogenic. One of these is
Trypanosoma (Megatrypanum) theileri, a cosmopolitan parasite of
bovids that infects most cattle worldwide [5–11]. Although one
report describes reduced milk yield in three infected cows [12], the
ubiquity of infection with this organism in cattle herds suggests
that it has no significant impact on health or productivity in
healthy animals, while cases of disease in immuno-compromised
animals are sufficiently rare as to merit individual case reports
[13–15]. The parasite is transmitted in the contaminated faeces of
tabanid flies and gains entry into the host through breaks in the
skin or via contamination of the oral mucosa [16]. Thereafter, it
lives extracellularly, being sustained at a low level (,100 organ-
isms/ml) for the life of the host. Being non-pathogenic, systemic,
related to the genetically well-characterised T. brucei, and sustained
long-term, we conceived that T. theileri would make a suitable
protein delivery system in cattle, able to generate immunity to
expressed antigens. As a naturally non-pathogenic kinetoplastid, T.
theileri offers considerable advantages over alternative vaccine
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delivery systems that comprise engineered, attenuated pathogens
such as Salmonella [17,18], Mycobacterium [19,20], E. coli [21], Vibreo
cholera, Listeria or Shigella [22]. Furthermore, being maintained over
long periods at low level, T. theileri offers the potential to generate
sustained immune responses of greater efficacy than conventional
vaccination approaches and to deliver therapeutic proteins of
benefit to bovine health or to limit the zoonotic potential of cattle
borne diseases.
Results
To develop T. theileri as a protein delivery system, the conditions
for its axenic in vitro growth and genetic manipulation were
established. To achieve this, a T. theileri isolate, originally identified
as a contaminant of a primary bovine reticulocyte culture, was
cultured under various conditions, optimal and sustained growth
being achieved using a semi-defined medium containing 50%
conditioned media from a bovine cell culture. In this medium, cell
densities of 16105 – 26106 cells/ml were achieved during routine
passage (Figure S1 in Text S1). Under these conditions, the
position of the kinetoplast (a specialised mitochondrial genome in
trypanosomatid parasites; [23]) varied in relation to the cell
nucleus but this was not clearly dependent upon the cell culture
density (Figure 1A, Figure S1 in Text S1). To generate stable
transfectants, bi-cistronic and tri-cistronic expression constructs
were developed that comprised a drug selectable marker gene and
a reporter gene, this being integrated into the small subunit 18S
ribosomal RNA gene locus (Figure 1B). Here, RNA polymerase I-
mediated read-through transcription can drive efficient gene
expression, transcripts being processed and capped via trans
splicing of a T. theileri-specific spliced leader (SL) RNA sequence,
matching the situation in other kinetoplastids [24,25]. This SL
sequence was identified by 59RACE of T. theileri transcripts and
matched the determined SL sequence of one previously isolated T.
theileri sample, T. theileri D30 (Figure S2 in Text S1; [26]), this
matching the trypanosomatid consensus. In order to drive effective
gene expression, RNA processing signals derived from T. theileri
were used. Since almost no molecular information for these
organisms was available, we isolated T. theileri intergenic sequences
using degenerate primers able to amplify between the coding
regions of well conserved genes (i.e. paraflagellar rod, tubulin,
actin genes) predicted from the analysis of other kinetoplastid
genomes to be tandemly arranged (Figure S3 in Text S1; [27]).
The resulting expression constructs were transfected into T. theileri
via nucleofector technology and selected using blasticidin or
phleomycin drug selection. Unlike other kinetoplastid organisms,
G418 and hygromycin B were not effective for selection in T.
theileri, wild type cells exhibiting high levels of resistance to these
drugs. This may have developed in natural T. theileri populations
through long-term use of aminoglycoside antibiotics for the
treatment of infections such as those responsible for bovine
mastitis.
In order to develop the system for the optimal delivery of
proteins to the bovine host, the potential to target expressed
Author Summary
Single-celled parasites of the order Kinetoplastida are
responsible for devastating diseases of humans and
animals, including African trypanosomiasis, Chagas’ dis-
ease and leishmaniasis. However, there are also many
species of trypanosomatids that do not cause disease and
are distributed globally. One example is Trypanosoma
(Megatrypanum) theileri, which is restricted to bovids and
ubiquitous in cattle herds worldwide. This organism is
maintained extracellularly in the blood and tissues long-
term without any observed ill effects on host health or
productivity. Using knowledge of gene expression and
protein trafficking in pathogenic trypanosomatids, we
have successfully developed, from first principles, Trypano-
soma theileri as a delivery system for vaccine antigens and
therapeutics. Procedures for the growth, transfection and
heterologous gene expression of T. theileri have been
developed, and the delivery of a vaccine antigen derived
from Babesia divergens evaluated in vivo. Our results
demonstrate the ability of T. theileri to be used as a flexible
and easily manipulated protein delivery system suitable for
the control of cattle pathogens and cattle-borne zoonoses.
In one notable application, we propose that the system
could allow the expression of serum trypanolytic factors in
cattle, with the potential to alleviate poverty in Africa
through the killing of pathogenic trypanosomatids in
livestock.
Figure 1. Heterologous proteins can be expressed and specifically localized in T. theileri. (A) An immunofluorescence image of
Trypanosoma theileri stained with antibody to T. brucei alpha tubulin; the kinetoplast and nuclear DNA is stained with DAPI (blue). (B) Schematic
representation of the integration of an expression cassette into the SSU rRNA locus of the T. theileri genome by homologous recombination. Read-
through transcription drives expression from the integrated cassette. (C) Expression vectors used to assay CAT protein expression in T. theileri, this
being as an unmodified protein (‘‘Native’’) or modified for secretion (‘‘N-BiP’’) or surface expression (‘‘N-BiP-GPI’’). For the N-BiP and N-BiP-GPI fusions,
two gene copies were inserted in tandem to improve overall expression, these being separated by the T. theileri beta-alpha tubulin intergenic region.
The respective distribution of CAT protein to the cell pellet or extracellular milieu is indicated on the right hand side, this being quantitated by CAT
ELISA assay.
doi:10.1371/journal.ppat.1002340.g001
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heterologous proteins to distinct cellular locations in T. theileri was
investigated. For secretion, fusion proteins were created compris-
ing the N-terminus of the T. brucei BiP/GRP78 protein
(PMID:8227199) (N-BiP), which in T. brucei targets proteins for
release into the extracellular milieu [28]. For cell surface
expression, signals providing a C-terminal GPI-addition sequence
were also added (N-BiP-GPI), whereas for internal expression,
native proteins were expressed. Quantitative expression analysis of
a chloramphenicol acetyl transferase (CAT) reporter protein
confirmed protein expression and accurate targeting, with the
percentage of protein released to the cell medium being 70% for
the N-BiP fusion, 7% for the N-BiP-GPI fusion and 15% for the
native protein, the latter probably including protein released from
dead cells in the culture (Figure 1C). Although the overall
expression efficiency was reduced considerably (10 to 50-fold) by
the inclusion of heterologous targeting signals (N-BiP, N-BiP-GPI),
this could be compensated somewhat by the expression of two
copies of the reporter gene in tandem, generating a tri-cistronic
construct (Figure 1C).
To evaluate T. theileri as a vaccine delivery system, cells were
engineered to express the Bd37 antigen from the cattle pathogen,
Babesia divergens [29]. In general, protection against Babesia is
thought to require components of the innate and adaptive immune
systems (Reviewed in [30]). Effector arms of the adaptive immune
system include antigen-specific antibodies, which have been
hypothesized to target both infected erythrocytes and extracellular
merozoites. There is also evidence that antibody-dependent cell-
mediated cytotoxicity (ADCC) plays a role in parasite control
during acute infection [31,32]. A recombinant version of the Bd37
protein has been shown to stimulate antibody-directed protective
immunity to B. divergens when administered in the context of an
adjuvant [33,34]. In our study, Bd37 protein was targeted for
internal expression, surface localization or extracellular release by
the expression of unmodified Bd37, N-BiP-Bd37-GPI or N-BiP-
Bd37 fusion proteins. Since anti-Bd37 antibody was not effective
in immunfluorescence assays, localisation was assessed for surface
and secreted expression by incubating non-permeabilised or 0.1%
TRITON X100 permeabilised cells with an antibody against T.
brucei BiP, this recognising the N-terminal BiP component of the
expressed fusion protein. In wild type cells, a signal was detected in
permeabilised cells (Figure 2 D–F), reflecting the recognition of T.
theileri BiP protein by antibody raised against T. brucei BiP.
However, as expected, non-permeabilised cells showed little
reactivity (Figure 2 A–C). In contrast, in transgenic T. theileri
expressing Bd37, a strong punctate signal was detected in non-
permeabilised cells for the N-BiP-Bd37-GPI fusion (Figure 2 M–
O), whereas N-BiP-Bd37 cells exhibited a somewhat weaker signal
concentrated close to the kinetoplast (Figure 2 G–I). This
supported a surface-associated expression for the N-BiP-Bd37-
GPI protein and flagellar pocket associated signal (the route for
protein secretion in trypanosomatids) for N-BiP-Bd37, although
staining of flagellar pocket-proximal vesicles cannot be excluded.
Transcripts generated from the expressed reporter constructs were
of the expected size, with the polyadenylation sites used for
mRNAs derived from each of the constructs being approximately
coincident with each other and with the site of beta tubulin
polyadenylation (Figure 3 and Figure S4 in Text S1).
Having established protein localisation at different cellular
locations, each T. theileri cell line was inoculated intravenously into
groups of cattle (internal expression, n= 6 animals; secreted
Figure 2. Cellular location of expressed N-BiP and N-BIP-GPI fusion proteins. Distribution of expressed Bd37 assayed via its fusion to T.
brucei BiP and detected using a BiP-specific antibody. Cells were fixed with paraformaldehyde and then either 0.1% Triton-X100 permeabilised, or not,
to distinguish intracellular from surface exposed protein following immunofluorescence. In wild-type cells, only weak staining was observed (A–C) in
the absence of permeabilisation whereas permeabilisation (D–F) allows visualisation of endogenous, intracellular T. theileri BiP protein, which cross-
reacts with the T. brucei BiP antibody. In contrast, the N-BiP-Bd37 fusion protein generates intense staining at the flagellar-pocket in intact cells (G–I),
plus an intense intracellular staining in permeabilised cells comprised of endogenous BiP and N-BiP-Bd37 protein in the ER (J–L). Expression of the N-
BiP-Bd37-GPI fusion protein generates a strong signal on intact cells indicating the presence of cell-surface protein (M–O); permeabilised cells also
show strong straining representing the combined endogenous BiP and the expressed fusion protein (P–R). Camera exposures with respect to the BiP
fluorescence and image handling were precisely consistent between cells under each condition to allow comparison of the relative intensity of signal.
DAPI images reveal the kinetoplast and nuclear position, these often overlying one another. Scale Bar = 10 mm.
doi:10.1371/journal.ppat.1002340.g002
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expression, n= 5 animals; surface expression, n= 6 animals), these
being maintained in a fly-free, high containment facility. Of these,
5 of the 17 animals had been found to contain a pre-existing
natural T. theileri population by screening blood using a specific,
nested PCR assay for the T. theileri tubulin gene array (Figure 4A).
Regardless of this, the transgenic T. theileri established in all
animals within one week, these being detectable by nested PCR
specific for the Bd37 gene present within the integrated expression
construct (Figure 4B). In each of the experimental groups, the
transgenic T. theileri was sustained in all animals throughout the 12
weeks after inoculation. This was without any adverse effects on
animal health being detected. Moreover, the transgenic T. theileri
could be recovered after several weeks of growth in cattle and was
found to maintain Bd37 gene expression (Figure 5).
To assess whether the inoculated animals were able to generate
a specific immune response to the delivered antigen, serum
samples were tested weekly for Bd37-specific IgG responses by
ELISA. Under all treatment conditions, sero-conversion was
observed, i.e. at least a 3-fold increase in ELISA OD compared to
pre-immunisation control sera from the same animal (Figure 6A–
C). Interestingly, the route of antigen expression affected both the
sero-conversion frequency and the resulting antibody titre, with
sero-conversion occurring in 4/6 animals receiving the cytosoli-
cally expressed antigen, 3/6 animals receiving the surface
expressed antigen, and 5/5 animals receiving the secreted antigen.
Moreover, the secreted antigen produced a significantly higher
end-point serum titre than either the surface expressed antigen
(Kruskal-Wallis one way ANOVA, p,0.05) or the cytosolically
expressed antigen (p,0.001) (Figure 6D), with antibody levels
continuing to increase for 60 days post inoculation before
plateauing and remaining high for at least a further 24 days
(Figure 6E). Inoculation of a further 16106 cells expressing the
secreted antigen on week 8 had no detectable stimulatory effect on
the levels of antibody generated (vertical arrow, Figure 6C, E).
To compare the antibody responses generated by transgenic T.
theileri with conventional immunisation approaches, the antibody
titres were assessed with respect to those established in a prime-
boost vaccination study using the same antigen. This demonstrat-
ed that the levels of anti-Bd37 antibody stimulated by the
transgenic T. theileri delivery system were equivalent to those
generated by the same antigen delivered in conventional adjuvant,
producing titres that are protective against Babesia in challenge
trials (dashed line, Figure 6D). Furthermore, the immune response
generated to the T. theileri-secreted Bd37 could effectively compete
with a monoclonal antibody able to confer passive immunity to
Babesia infection in a gerbil model (Figure 6F), demonstrating the
recognition of common, potentially protective epitopes. Com-
bined, these assays confirm that T. theileri represents an effective
antigen delivery system able to generate sustained immune
responses equivalent to, or exceeding, those generated by standard
vaccination and at levels known to be protective against a target
pathogen.
Discussion
Our work describes a naturally non-pathogenic eukaryotic
organism, T. theileri, engineered to deliver antigens and therapeutic
proteins to cattle. Importantly, T. theileri is a flexible and adaptable
system for the targeted expression of individual, or cocktails of
multiple, heterologous proteins simultaneously. This allows for the
targeting of different pathogens, or multiple defined antigens of a
specific pathogen, providing an effective approach to limiting the
transmission of disease from livestock to man, as well as
maintaining bovine health and maximising bovine productivity.
This system has many advantages over traditional vaccine delivery
technologies, including the possibility of oral delivery, a natural
route of T. theileri infection, and the potential for sustained immune
stimulation through prolonged infection without adverse conse-
quence on productivity or health. It also provides an explicit
example of an unanticipated applied benefit derived from the
extensive research investment in the basic biology of kinetoplastid
pathogens.
A number of kinetoplastid parasites have been successfully
transfected to drive ectopic expression of endogenous genes or
heterologous expression of reporter genes[35] . In general, these
have been used for the analysis of gene function in the transfected
organisms or for protein expression in vitro. In particular, the
kinetoplastid protozoa T. brucei, Crithidia fasciculata, Leishmania
amazonensis and Leishmania tarentolae have each been engineered as
eukaryotic vehicles for the expression of proteins which are
appropriately post-translationally modified, that retain biological
activity, or which are suitable for meaningful inhibition studies for
drugs targeted against kinetoplastids [36–40]. In each case, the
basic organisation of the expression vectors employed was similar.
However, there is no predictable cross functionality of RNA
processing signals . For example, in one study, transfection of a
range of kinetoplastid protozoa with a common expression
construct developed in Leishmania major resulted in reporter gene
expression in other Leishmania spp., but not in T. brucei or T. cruzi
[41].
The specificity of RNA processing signals among kinetoplastids
necessitated that we isolated intergenic sequences from T. theileri.
To our knowledge, no protein coding gene sequence have been
characterised in these organisms to date. Despite this, we were able
to make use of the tandem arrangement of several conserved
housekeeping genes in trypanosomatids to isolate intergenic
Figure 3. Transcript expression of exogenous genes in
transgenic T. theileri. Northern blots of untransfected T. theileri and
T. theileri engineered to express native Bd37, N-BiP Bd37 (‘Bd37
secreted’) or N-BiP Bd37 GPI (‘Bd37 surface’), transcripts being detected
using a riboprobe detecting Bd37. Respective loading is indicated by
the Ethidium bromide stained rRNA (lower panel).
doi:10.1371/journal.ppat.1002340.g003
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sequences between alpha and beta tubulin genes, beta and alpha
tubulin genes, actin genes and the PFR genes. Conservation in
these genes allowed successful amplification between genes using
degenerate oligonucleotides. In each case, the predicted protein
sequences were highly similar to those in other kinetoplastids over
the sequenced region, this being reinforced by the reactivity of
monoclonal antibodies specific for alpha tubulin, PFRA and BiP in
T. brucei with T. theileri (Figure 1A, Figure 2 and data not shown).
Extensive protein coding similarity is also evident from a whole
genome analysis of T. theileri that we have recently completed (our
unpublished observations). Despite this similarity in coding
regions, there was no recognisable similarity in the intergenic
regions of each gene between species. This emphasised the
requirement to use endogenous intergenic sequences in the
developed expression constructs. Indeed, transient transfection of
T. theileri with a reporter construct generated for use in T. brucei did
not result in detectable heterologous gene expression (unpublished
observations). Cloning and sequencing of 59RACE products
derived from the actin gene transcript identified the SL sequence
common to all trypanosomatid mRNAs. Interestingly, the
sequence of the leader RNA did not match the SL sequence of
a previous T. theileri isolate (K127), which was reported to exhibit a
1 nucleotide distinction from the sequence identified on the
majority of trypanosomatid parasites . Instead, the leader sequence
identified in the isolate of T. theileri used in our study matched
exactly the trypanosomatid consensus and shared with T. theileri
D30 . This suggests variation in this sequence amongst different T.
theileri isolates.
Previous approaches have used kinetoplastid parasites as
vehicles for protein expression in vitro, or for potential medicinal
use via expression of biomolecules from attenuated pathogens in
vivo. In these, and other cases of pathogen-based vaccine vectors
(for example, using attenuated Salmonella , Mycobacterium , E. coli , V.
cholera, Listeria or Shigella), the vehicles have a potential to revert to
pathogenicity raising issues of long-term efficacy and safety.
Moreover, recombination with non-attenuated pathogens can
generate vaccine escape mutants, as observed after pneumococcal
vaccination in the USA [42]. By exploiting an already non-
pathogenic organism (T. theileri) for protein expression in its natural
host, the possibility of reversion to, or unanticipated, pathogenicity
is greatly reduced. Supporting this, the T. theileri isolate used in our
studies has been maintained in tissue culture for over 6 years and
yet, when inoculated into cattle, generated no ill effects and was
sustained at low abundance throughout a 12-week trial. The
transgenic parasites could also establish and be sustained in the
context of a pre-existing natural infection. This is an important
Figure 4. Inoculation with the vaccine vehicle results in successful establishment of the population in cattle. (A) Schematic
representation of the amplicon used to detect T. theileri genomic DNA. The amplicon, specific for the T. theileri tubulin gene array, will detect both
endogenous T. theileri infection and the presence of the transgenic vaccine vehicle. PCR products were derived from individual calves either before
inoculation with transgenic T. theileri, or 1 week and 12 weeks post inoculation. Prior to inoculation 5/17 animals harboured a naturally occurring T.
theileri population. (B) A second amplicon specific for the expressed Bd37 gene detects only genomic DNA from the transgenic T. theileri. The cattle
all became positive for the transgenic vaccine vehicle within 1 week, regardless of their original infection status, this being sustained throughout the
12 weeks of the experiment for all animals.
doi:10.1371/journal.ppat.1002340.g004
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consideration since T. theileri is almost ubiquitous in cattle herds
worldwide with, for example, 44%–80% incidence levels reported
in New York State and up to 93% in Louisiana [43]. A survey of
local adult cattle in Edinburgh revealed that all animals tested (16/
16) were positive for T. theileri infection by the nested PCR assay
for tubulin intergenic sequence (data not shown).
T. theileri has clear potential as a flexible vaccine vehicle, able to
target a wide range of pathogens, including viruses (e.g. Foot and
Mouth Disease Virus, Bovine Viral Diarrhea Virus), bacteria (e.g. E.
coli, Salmonella spp., Campylobacter spp., Brucella spp. and mycoba-
teria), ectoparasites (e.g. ticks, mites, lice) as well as pathogenic
eukaryotic parasites (Babesia spp., Neospora caninum, Coccidia spp.,
Trichomonas spp. and helminths). However, T. theileri also has
potential to deliver therapeutic proteins such as antimicrobials
systemically in cattle, able to limit the impact of bacterial infections,
for example. Furthermore, we propose that it may be possible to
avoid the need to engineer transgenic cattle to express ApoLI or
mutant variants [44,45], allowing indigenous and disease-resistant
African livestock to combat pathogenic trypanosome infection via
T. theileri directed ApoL1 expression. Such an approach would
require that the ApoL1 is expressed in a form that is non-
immunogenic and active in cattle. Nonetheless, this could provide a
simple and cost effective route to limiting the effects of trypanosome
infection on the productivity or zoonotic potential of indigenous
African cattle. This has the potential to increase their productivity
and eliminate an important reservoir for human disease, alleviating
poverty and disease in afflicted regions.
Materials and Methods
Ethics statement
Animal trials in this manuscript were reviewed and approved
through the ethical review committee at Moredun Research
Institute (Experiment approval no. E28/10). Experiments were
carried out under a UK Home Office Licence (PPL 60/4044) in
accordance with the UK Animals (Scientific Procedures) Act,
1986.
Cell culture
Bovine conditioned media was produced by growing Madin-
Darby Bovine Kidney (MDBK) cells in Eagle’s Minimum Essential
Medium with Earle’s Balanced Salt Solution and sodium
bicarbonate (Sigma, M2279) supplemented with 1% MEM non-
essential amino acids (Invitrogen, 11140), 1% L-Glutamine
solution (from 200 mM solution, Sigma, G7513), and 10% FCS
until confluence (2–3 days). The MDBK-conditioned media was
then harvested and filtered prior to use. T. theileri were cultured in
50% HMI-9 medium [46] supplemented with 20% FCS and 10%
Serum+ and 50% MDBK-conditioned media as described above.
Creation of recombinant cell lines
The plasmid backbone used for construction of all expression
vectors was derived from the pGemT Easy plasmid (Promega). All
elements of the vector were prepared through PCR of the noted
sequence, followed by cloning into the vector backbone, and
construction was accomplished through the insertion of appropri-
ate restriction sites at the 59 and 39 ends of each segment. The
segments used for the construction of the expression cassettes and
the corresponding primers used in this study include: the 59
fragment of the T. theileri SSU rRNA gene (SSU5-ApaI-For and
SSU5-AvrII-Rev), the 39 fragment of the T. theileri SSU rRNA
gene (SSU3-PacI-For and 3SSU-Rev-XmaI), the trans-splicing
addition site from the actin IR sequence (splice-AvrII-For and
splice-FseI-Rev), the Bd37 coding sequence (Bd37-Core-F-FseI or
Bd37-Core-F-AvrII and Bd37-Core-F-AvrII and Bd37-Core-R-
HindIII), the CAT coding sequence (CAT For FseI or CAT For
XhoI and CAT Rev XbaI or CAT Rev AscI), the blasticidin
resistance cassette (BSDKpn-F and BSDBgl-R), the beta-alpha
tubulin IR sequence (ba-tub-AscI-For or ba-tub-BglII and ba-tub-
KpnI-Rev or ba-tub-PacI), the T. brucei BiP N-terminal fragment
sequence (BiP-For-FseI or BiP-For-FseI-SpeI and BiP-Rev-XhoI),
and the GPI addition signal (GPI-For-HindIII and GPI-Rev-AscI).
In fusion protein cassettes, care was taken to preserve the reading
frame and appropriate start and stop codons were provided. The
plasmids containing the expression cassettes were then digested
with appropriate restriction enzymes to liberate the plasmid
backbone from the linear expression cassette, which was isolated
via gel electrophoresis and gel purification. The linear cassette was
then purified by ethanol precipitation and resuspended in 5 ml of
TE buffer (1 mM Tris-HCl (pH 8) and 0.1 mM EDTA).
From a culture of logarithmically growing T. theileri parasites,
10 ml of culture at ,56105 cells/ml were used for each
transfection. Cells were centrifuged at 10006 g, for 10 minutes
Figure 5. Sustained transgene expression in T. theileri after
growth in cattle. Northern Blot to determine N-BiP Bd37 transcript
expression in cultured T. theileri cells used to inoculate cattle, or
harvested after 3 weeks growth in inoculated cattle. Expression of the
Bd37 transcript was maintained. Respective loading is indicated by the
Ethidium bromide staining rRNA (lower panel).
doi:10.1371/journal.ppat.1002340.g005
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at room temperature and resuspended in 1 ml of sterile PBS to
wash the cells. Cells were then re-centrifuged and resuspended in
100 ml Ingenio transfection buffer (Mirus Bio). The cells were
added to the prepared linear DNA and transferred to a cuvette for
the Nucleofector II electroporation device (Lonza). Transfection
was done with Nucleofector program X-001 (recommended for
mouse CD8+ T cells) and cells transferred to a culture flask
containing 10 ml of pre-warmed media and incubated for 24 hrs
at 37uC, in 5 % CO2. Cells were then transferred to media
containing the selective drug concentration (10 mg/ml of blas-
ticidin) and plated using a variety of dilutions into a 24-well cell
culture plate. After selection clones were recovered under normal
cell culture conditions.
Immunofluorescence assay
The localisation of the BiP-Bd37 fusion protein was determined
using 2% paraformaldehyde fixed cells permeabilised, or not, with
TBS: 0.1% Triton X-100 for 2 minutes. Cells were quenched for
30 minutes with TBS:0.1% glycine and then blocked for 1 hr with
TBS: 1%BSA. Cells were then reacted with anti-BiP antibody (a
gift of Jay Bangs, University of Wisconsin) diluted 1:200 in
TBS:1%BSA, washed three times with TBS and then incubated
with anti-rabbit FITC conjugated antibody (Sigma) diluted 1:100
inTBS:1%BSA. Prior to mounting in MOWIOL, cells were
stained with 49, 6-diamidino-2-phenylindole for 5 minutes to
visualize cellular DNA.
Experimental animals, sampling and DNA extraction
Calves (6-weeks old) were injected intravenously with 16105 T.
theileri parasites. Blood samples were taken weekly into EDTA-
containing tubes (Becton-Dickinson) and DNA extracted. DNA
extraction from whole blood samples was performed as follows:
1 ml of blood was mixed thoroughly with 0.5 ml of RBC lysis
buffer (0.32 M sucrose, 10 mM Tris-HCl pH 7.5, 5 mM MgCl2,
Figure 6. Inoculation with the vaccine vehicle stimulates an effective antibody response to the expressed antigen. (A-C)
Quantification of anti-Bd37 antibody responses by ELISA assay demonstrate that calves exposed to Bd37 that is expressed at an internal (A) or surface
location (B) on T. theileri, or is secreted (C), show sero-conversion (filled circles) within 12 weeks of inoculation. Animals that did not sero-convert are
shown as open circles. (D) End-point titres measured for all experimental animals show that those cattle receiving secreted Bd37 achieved
significantly higher antibody levels than the other treatment groups (* p,0.05, ** p,0.001). (E) Time-course of antibody response to secreted Bd37
vaccine vehicle in all cattle. (F) Sera from vaccinated animals are able to compete with an anti-Bd37 monoclonal antibody for ELISA binding; assay
details are provided in the ‘Materials and Methods’. Vertical arrows in Panels C and E indicate inoculation of a further 16106 transgenic T. theileri.
doi:10.1371/journal.ppat.1002340.g006
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0.75% Triton X-100) in a microfuge tube. The samples were then
centrifuged at 14, 000 rpm for 1 minute to pellet all cells and the
supernatant removed. The pellets were repeatedly resuspended
and recovered from 0.5 ml aliquots of RBC lysis buffer until no
red blood cells were present. The resulting pellets were
resuspended in 100 ml of lysis buffer (50 mM KCl, 10 mM Tris-
HCl pH 8.3, 2.5 mM MgCl2, 0.1 mg/ml gelatin, 0.45% NP40,
0.45% Tween-20, 60 mg/ml proteinase K) and kept at 55uC for 60
minutes. The samples were then incubated at 95uC for 10 minutes
prior to storage at 220uC until use.
Nested PCR
Nested PCR reactions were designed to amplify either the T.
theileri b-a tubulin intergenic sequence (to identify any T. theileri
population) or the Bd37 coding sequence (specific for the vaccine
vehicle). The primers used were as follows:
Tub Diagnostic F1: 59-AGTAGCAACGACAGCAGCAGT-39
Tub Diagnostic R1: 59-GTAAAGTGTTTGAAGAAGAGC-
TCG-39
Tub Diagnostic F2: 59-CGATTCTCTTCGCCTGTTTGT-39
Tub Diagnostic R2: 59-ACTAACCGCGACCAAAGAAGT-39
Bd37 Diagnostic F1: 59-GCTCACAGGAGCCAGCAGCGG-39
Bd37 Diagnostic R1: 59-CCAGAGCTTTGAGATTAGCT-
GGTA-39
Bd37 Diagnostic F2: 59-ACGCAGCAAGGTGGTGCGAA-39
Bd37 Diagnostic R2: 59-AGCAAGGCCTCACCGCCCT-
TGGC-39
Each 25 ml reaction contained the following components: 5 ml
of template, 1X PCR buffer, 0.2 mM of each dNTP, 1.25 mM
MgCl2, 0.4 mM of each primer and 0.25 U GoTaq Flexi DNA
Polymerase (Promega). The first stage PCR reactions were heated
to 95uC for 5 minutes, followed by 35 cycles of denaturation at
95uC for 30 seconds, annealing at 60uC for 45 seconds and
elongation at 72uC for 45 seconds. Following the final cycle, the
reactions were elongated for a further 4 minutes. The second stage
nested PCR reaction was conducted using the same conditions
with 5 ml of the first reaction as template. The resulting products
were electrophoresed on a 1% Tris-acetic acid-EDTA agarose gel,
stained with ethidium bromide and visualized.
Serum preparation and ELISA assay
Serum samples were prepared from 10 ml of fresh blood and
stored at 220uC until use. Recombinant (E. coli) expressed His-
tagged Bd37 antigen was diluted to 5 mg per ml in coating buffer
(0.01 M sodium carbonate pH 9.6), and 100 ml were added to
each well of microtiter plates and incubated overnight at 37uC.
The coating buffer was removed and 200 ml blocking buffer (10%
horse serum in 10 mM PBS) were added, and incubated at 37uC
for 60 minutes. The plates were washed 3 times with 200 ml
washing buffer (10 mM PBS, pH 9.6 with 1% Tween-20). Bovine
serum samples were diluted in blocking buffer as appropriate, and
100 ml were incubated in the coated and incubated at 37uC for 60
minutes. For standard ELISA plates were washed and incubated
with HRP-conjugated anti-bovine IgG antibody diluted 1:1000 in
blocking buffer and incubated at 37uC for 60 minutes. For
competitive ELISA assays, 100 ml of mouse monoclonal anti-Bd37
antibody (1 mg/ml diluted 1:1000 in blocking buffer) were added
to each well and incubated at 37uC for 60 minutes. Plates were
washed and incubated with HRP-conjugated anti-mouse IgG
antibody diluted 1:1000 in blocking buffer and incubated at 37uC
for 60 minutes. Plates were washed, treated with TMB
supersensitive substrate (Sigma), stopped with 2M sulphuric acid
and the OD was measured at 450 nm in an ELISA plate reader.
Statistics
To analyse serum antibody titres, a Kruskal-Wallis one way
ANOVA was used.
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